Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
14
×
boston blog main
boston top stories
14
×
life sciences
national blog main
national top stories
clinical trials
biotech
drugs
fda
new york blog main
alnylam pharmaceuticals
new york top stories
patisiran
rna interference
san francisco blog main
akcea therapeutics
editas medicine
hereditary transthyretin amyloidosis
inotersen
onpattro
san diego blog main
san diego top stories
san francisco top stories
tafamidis
aminolevulinic acid
broad institute
cancer
crispr
david liu
deals
foundation medicine
gene editing
givosiran
licensing
pfizer
roche
vyndaqel
abbvie
accelerated approval
What
medicine
14
×
fda
drug
alnylam
rna
gene
new
rnai
interference
patients
pharmaceuticals
second
therapeutics
ago
approval
approved
billion
cells
crispr
data
editas
editing
historic
market
ok
puts
recently
rest
roche
seek
specifically
speedy
therapy
uses
acquire
advance
afternoon
agreed
aldeyra
allergan
Language
unset
Current search:
boston
×
medicine
×
" boston top stories "
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com
5 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Digital Tools, Online Community & More: Patient Partnership Award Finalists
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M